Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

Table of Content

---

1. Report Overview
1.1 Global Rheumatoid Arthritis Drugs Market Overview
1.2 Overview of Findings
1.3 Structure of the Report
1.4 Global Rheumatoid Arthritis Drugs Market Segmentation
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8. Who is This Report For?
1.9 Methodology

2. Introduction to Rheumatoid Arthritis Drugs
2.1 What is Rheumatoid Arthritis?
2.2 What Causes Rheumatoid Arthritis?
2.3. How Does the Disease Develop?
2.4. How Can It Be Monitored?
2.5. Can RA Be Cured?
2.6. Performance Criteria Used in Clinical Trials
2.6.1. ACR Criteria for Drug Efficacy
2.6.2. HAQ-DI Measures Daily Activities
2.6.3. mSS Assesses Disease on X-Ray
2.6.4. DAS28 For Disease Severity
2.7. How is RA Treated?
2.7.1 Biologic DMARDs Are the Dominant Source of Revenue
2.7.2 Synthetic DMARDs are the Mainstay of Treatment
2.7.3 Others
2.7.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2.7.3.2 Corticosteroids for Rapid Anti-Inflammatory Effect
2.7.3.3 Analgesics for Rapid Pain Relief
2.8 Comorbid Conditions Associated with RA
2.9 Prevalence and Incidence Rates of Rheumatoid Arthritis

3. Rheumatoid Arthritis Drugs Market, 2020-2030
3.1 The Global Rheumatoid Arthritis Drugs Market: Market Overview
3.2 Global Rheumatoid Arthritis Drugs Market: Revenue Forecast 2020-2030
3.3 Global Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
3.4 Changing Market Shares by Segment 2020-2030
3.5 Non-Biologics for RA
3.5.1 NSAIDs: Revenue Forecast, 2020-2030
3.5.2 Synthetic DMARDs (sDMARDs): Revenue Forecast, 2018-2030
3.5.3 Others: Revenue Forecast, 2018-2030

4. Leading Drugs in the Rheumatoid Arthritis Market 2020-2030
4.1 The Main Drugs in the Rheumatoid Arthritis Market, 2018
4.2 Humira: A Major Source of Revenue for AbbVie
4.2.1 Adalimumab Biosimilars
4.2.2 Humira: Sales Forecast 2020-2030
4.3 Enbrel: Amgen’s Revenue Protected Until 2030
4.3.1 Etanercept Biosimilars
4.3.2 Enbrel: Revenue Forecast 2020-2030
4.4 Remicade: Facing Significant Competition from Biosimilars
4.4.1 Infliximab Biosimilars
4.4.2 Remicade: Revenue Forecast 2018-2030
4.5 Rituxan: Facing Declining Market Share
4.5.1 Rituximab Biosimilars
4.5.2 Rituxan: Revenue Forecast 2018-2030
4.6 Simponi (golimumab): Market Share Remaining Stable
4.6.1 Simponi/Simponi Aria: Revenue Forecast 2018-2030
4.7 Orencia: Additional Indications Being Explored
4.7.1 Abatacept Biosimilars
4.7.2 Orencia: Revenue Forecast 2018-2030
4.8 Actemra/RoActemra: First IL-6R Inhibitor Approved for RA
4.8.1 Tocilizumab Biosimilars
4.8.2 Actemra/RoActemra: Revenue Forecast 2018-2030
4.9 Cimzia: Reliable Source of Income for UCB
4.9.1 Certolizumab Biosimilars
4.9.2 Cimzia: Revenue Forecast 2018-2030
4.10 Celebrex: Facing Generic Competition
4.10.1 Celebrex: Revenue Forecast 2018-2030
4.11 Xeljanz: Good Opportunity for Revenue Growth
4.11.1 Xeljanz: Revenue Forecast 2018-2030
4.12 Arcoxia: Sales Revenue Already Declining
4.12.1 Arcoxia: Revenue Forecast 2018-2030

5. Leading National Markets 2020-2030
5.1. Geographical Breakdown of the World Rheumatoid Arthritis Drugs Market
5.2 World Rheumatoid Arthritis Drugs Market: Regional Forecast 2020-2030
5.2.1 How Will Regional Market Shares Change to 2030?

6. North America Rheumatoid Arthritis Drugs Market, 2020-2030
6.1. US Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
6.2. Canada Rheumatoid Arthritis Drugs Market: Trends and Developments

7. Europe Rheumatoid Arthritis Drugs Market 2020-2030
7.1 Europe Markets: Changing Market Shares by Country, 2020-2030
7.2. Germany Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
7.3. France Rheumatoid Arthritis Drugs Market: Trends and Developments
7.4. U.K. Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
7.5. Italy Rheumatoid Arthritis Drugs Market: Trends and Developments
7.6. Spain Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
7.7. Russia Rheumatoid Arthritis Drugs Market: Trends and Developments
7.8. Rest of Europe Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

8. Asia-Pacific Rheumatoid Arthritis Drugs Market 2020-2030
8.1. Japan Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
8.2. China Rheumatoid Arthritis Drugs Market: Trends and Developments
8.3. India Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
8.4. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market: Trends and Developments

9. Latin America Rheumatoid Arthritis Drugs Market, 2020-2030
9.1. Brazil Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
9.2. Mexico Rheumatoid Arthritis Drugs Market: Trends and Developments
9.3. Rest of Latin America Rheumatoid Arthritis Drugs Market: Trends and Developments

10. Middle East & Africa Rheumatoid Arthritis Drugs Market, 2020-2030
10.1. Saudi Arabia Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030
10.2. South Africa Rheumatoid Arthritis Drugs Market: Trends and Developments
10.3. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market: Trends and Developments

11. Rheumatoid Arthritis R&D Pipeline 2019

12. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2019
12.1 Introduction to the Leading Companies
12.2 AbbVie: Secured Multiple Patents for Humira
12.2.1 Overview
12.2.2 AbbVie: Rheumatoid Arthritis Drugs Product Portfolio
11.2.3 AbbVie: Financial Overview
12.2.4 AbbVie: Recent Transactions Summary
12.3 F. Hoffmann-La Roche Ltd (Roche)
12.3.1 Overview
12.3.2 Roche: Financial Overview
12.3.3 Recent Transactions Summary
12.4 Johnson & Johnson
12.4.1 Overview
12.4.2 Johnson & Johnson: Financial Overview
12.4.3 Johnson & Johnson: Recent Transactions Summary
11.5. Amgen, Inc.
12.5.1 Overview
12.5.2 Amgen Inc.: Financial Overview
12.5.3. Amgen Inc.: Recent Transactions Summary
12.6. Pfizer: Actively Developing Biosimilars
12.6.1 Overview
12.6.2 Pfizer, Inc.: Financial Overview
12.6.3 Pfizer, Inc.: Recent Transactions Summary
12.7 Merck & Co., Inc.: Remicade Sales in Decline
12.7.1. Overview
12.7.2 Merck & Co., Inc.: Financial Overview
12.7.3 Merck & Co., Inc.: Recent Transactions Summary
12.8. Bristol-Myers Squibb (BMS): Exploring Additional Indications for Orencia
12.8.1. Overview
12.8.2 Bristol-Myers Squibb: Financial Overview
12.8.3 Bristol-Myers Squibb: Recent Developments
12.9. UCB: Reliant on Cimzia Revenue
12.9.1 Overview
12.9.2 UCB: Financial Overview
12.9.3 UCB: Recent Developments
12.10. Eli Lilly and Company
12.10.1 Eli Lilly and Company: Rheumatoid Arthritis Drugs Portfolio
12.10.2 Eli Lilly and Company: Financial Overview
12.10.3 Eli Lilly and Company: Recent Transactions Summary
12.11. Novartis AG
12.11.1 Novartis AG: Rheumatoid Arthritis Drugs Portfolio
12.11.2 Novartis AG: Financial Overview
12.11.3 Novartis AG: Recent Transactions Summary
12.12. Sanofi S.A. (Sanofi)
12.12.1 Sanofi S.A.: Rheumatoid Arthritis Drugs Portfolio
12.12.2 Sanofi: Financial Overview
12.12.3 Sanofi S.A.: Recent Transactions Summary

13. Qualitative Analysis of the Rheumatoid Arthritis Market
13.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market
13.1.1 Strengths
13.1.1.1 Number of Elderly Patients Expected to Rise
13.1.1.2 Biologics Already Recognised as a Valuable Part of Treatment
13.1.1.3 Biologics Used in RA Often Have Multiple Indications
13.1.2 Weaknesses
13.1.2.1 Some Patients Have an Inadequate Treatment Response
13.1.2.2. Efficacy of Drugs Can Diminish Over Time
13.1.3. Opportunities
13.1.3.1 Need for Effective Drugs with Better Safety Profiles
13.1.3.2 Need for Less Invasive Route of Administration
13.1.4. Threats
13.1.4.1 High Number of Products Will Saturate Market
13.1.4.2 Competition from Biosimilars Will Increase
13.2 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis)
13.2.1 Social Factors Influencing the Rheumatoid Arthritis Market
13.2.2 Technological Factors Influencing the Rheumatoid Arthritis Market
13.2.3 Economic Factors Influencing the Rheumatoid Arthritis Market
13.2.4 Political Factors Influencing the Rheumatoid Arthritis Market
13.2.4.1 Government Pressure to Control Costs
13.2.4.2 Inter-country Variability in Biosimilar Approval Process

14. Conclusions
14.1 Overview of Current Market Conditions and Market Forecast
14.2 Biologics Will Remain Dominant Drug Class but their Market Share Will Drop More than 20%
14.3 Enbrel Will Overtake Humira as the Leading Drug
14.4 Leading Regions in the Rheumatoid Arthritis Market in 2018
14.5 Trends in the RA Drugs Market

List of Table
Table 2.1 Biologic Agents and Mechanism of Action
Table 2.2 Comorbidities Associated with RA in Different Organs
Table 2.3 Prevalence rate of RA in Different Countries
Table 3.1 Rheumatoid Arthritis Drugs Market by Submarket, 2018
Table 3.2 The Global Rheumatoid Arthritis Drugs Market: Revenue ($m) and Market Shares (%) by Type, 2018 and 2019
Table 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 3.4 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 3.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: CAGR (%), 2020-
2024, 2024-2030, 2020-2030
Table 3.6 Non-Biologics for Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR
(%), CAGR (%), 2018-2030
Table 3.7 NSAIDs for Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%)
and CAGR (%), 2018-2030
Table 3.8 sDMARDs for Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%)
and CAGR (%), 2018-2030
Table 3.9 Others for Rheumatoid Arthritis Forecasts: Revenue ($m), AGR (%) and CAGR
(%), 2018-2030
Table 4.1 Global Rheumatoid Arthritis Market by Drugs Classs: Revenue ($m), and
Market Share (%), 2018
Table 4.2 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue
($m), AGR (%) and CAGR (%), 2018-2030
Table 4.3 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
Table 4.4 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030
Table 4.5 Humira: Key Facts
Table 4.6 Adalimumab Biosimilars: Current Status, 2019
Table 4.7 Global Humira Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.8 Enbrel: Key Facts
Table 4.9 Etanercept Biosimilars: Current Status, 2019
Table 4.10 Global Enbrel Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-
2030
Table 4.11 Remicade: Key Facts
Table 4.12 Infliximab Biosimilars: Current Status, 2019
Table 4.13 Global Remicade Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.14 Rituxan: Key Facts
Table 4.15 Rituximab Biosimilars: Current Status, 2019
Table 4.16 Global Rituxan Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.17 Simponi: Key Facts
Table 4.18 Global Simponi/Simponi Aria Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.19 Orencia: Key Facts
Table 4.20 Global Orencia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.21 Actemra/RoActemra: Key Facts
Table 4.22 Global Actemra/RoActemra Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.23 Cimzia: Key Facts
Table 4.24 Global Cimzia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.25 Celebrex: Key Facts
Table 4.26 Global Celebrex Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.27 Xeljanz: Key Facts
Table 4.28 Global Xeljanz Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 4.29 Arcoxia: Key Facts
Table 4.30 Global Arcoxia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030
Table 5.1 Global Rheumatoid Arthritis Drugs Market by Region: Revenue ($ m), 2018 and
2019
Table 5.2 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($ m), AGR (%),
CAGR (%), 2018-2030
Table 5.3 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2020-2024,
2024-2030, 2020-2030
Table 5.4 Global Rheumatoid Arthritis Drugs Market by Region: Market Share (%), 2019, 2024, 2030
Table 6.1 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 6.2 North America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by
Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 6.3 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues
($ m), AGR (%), CAGR (%), 2018-2030
Table 6.4 U.S.Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 6.5 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR
(%), CAGR (%), 2018-2030
Table 7.1 Europe Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue
($m) and Market Share (%), 2018
Table 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m),
AGR (%), CAGR (%), 2018-2030
Table 7.3 Europe Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by
Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 7.4 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 7.5 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m),
AGR (%), CAGR (%), 2018-2030
Table 7.6 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2020-2024,
2024-2030, and 2020-2030
Table 7.7 Germany Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($
m), AGR (%), CAGR (%), 2018-2030
Table 7.8 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 7.9 U.K.Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m),
AGR (%), CAGR (%), 2018-2030
Table 7.10 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 7.11 Spain Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 7.12 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR
(%), CAGR (%), 2018-2030
Table 7.13 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast by Country:
Revenues ($ m), AGR (%), CAGR (%), 2018-2030
Table 8.1 Global Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue ($
m) and Market Share (%), 2018
Table 8.2 Asia Pacific Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 8.3 Asia Pacific Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by
Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 8.4 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 8.5 Japan Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m),
AGR (%), CAGR (%), 2018-2030
Table 8.6 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 8.7 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 8.8 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 9.1 Latin America Rheumatoid Arthritis Drugs Market by Country/Sub-region:
Revenue ($m) and Market Share (%), 2018
Table 9.2 Latin America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 9.3 Latin America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by
Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 9.4 Latin America Rheumatoid Arthritis Drugs Market Forecast by Country:
Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 9.5 Brazil Rheumatoid Arthritis Drugs Market Forecast, By Country: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 9.6 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2018-2030
Table 9.7 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues
($m), AGR (%), CAGR (%), 2018-2030
Table 10.1 Middle East & Africa Rheumatoid Arthritis Drugs Market by Country/Sub-
region: Revenue ($ m) and Market Share (%), 2018
Table 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast by Class:
Revenues ($ m), AGR (%), CAGR (%), 2018-2030
Table 10.3 Middle East & Africa Rheumatoid Arthritis Drugs (Non-Biologics) Market
Forecast by Segment: Revenues ($ m), AGR (%), CAGR (%), 2018-2030
Table 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast by Country:
Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 10.5 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast by Country:
Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 10.6 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($ m),
AGR (%), CAGR (%), 2018-2030
Table 10.7 Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast:
Revenues ($m), AGR (%), CAGR (%), 2018-2030
Table 11.1 Pipeline R&D Products, 2019
Table 11.2 Other RA Pipeline R&D Products, 2019
Table 12.1 Leading Companies in the RA Drug Market: Revenue ($m) and Market Share
(%), 2018
Table 12.2 AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.3 AbbVie: Overview, 2019
Table 12.4 AbbVie: Revenue ($m), AGR (%), 2014-2018
Table 12.5 F.Hoffmann-La Roche AG:: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.6. Roche: Overview, 2019
Table 12.7 Roche: Revenue ($m), AGR (%), 2014-2018
Table 12.8 Johnson & Johnson: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.9. Johnson & Johnson: Overview, 2019
Table 12.10 Johnson & Johnson: Revenue ($m), AGR (%), 2014-2018
Table 12.11 Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.12 Amgen, Inc.: Overview, 2019
Table 12.13 Amgen Inc.: Revenue ($m), AGR (%), 2014-2018
Table 12.14 Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.15 Pfizer, Inc.: Overview, 2019
Table 12.16 Pfizer, Inc.: Revenue ($m), AGR (%), 2014-2018
Table 12.17 Merck & Co., Inc.: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.18 Merck & Co., Inc.: Overview, 2019
Table 12.19 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
Table 12.20 Bristol-Myers Squibb: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.21 Bristol-Myers Squibb: Overview, 2019
Table 12.22 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2014-2018
Table 12.23 UCB: Breakdown of Revenue ($m,%) by RA Drug, 2018
Table 12.24 UCB: Overview, 2019
Table 12.25 UCB: Revenue ($m), AGR (%), 2014-2018
Table 12.26 Eli Lilly and Company: Overview, 2019
Table 12.27 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018
Table 12.28 Novartis AG: Overview, 2019
Table 12.29 Novartis AG: Revenue ($m), AGR (%), 2014-2018
Table 12.30 Sanofi S.A.: Overview, 2019
Table 12.31 Sanofi: Revenue ($m), AGR (%), 2014-2018
Table 13.1 SWOT Analysis of the Global Rheumatoid Arthritis Market, 2020-2030
Table 13.2 Social, Technological, Economic and Political Factors Influencing the RA
Market, 2018-2030
Table 14.1 Global Rheumatoid Arthritis Market Forecast: Revenue ($m), and CAGR (%),
2018, 2024 and 2030
Table 14.2 Global Rheumatoid Arthritis Market by Drugs Class: CAGR (%), 2018, 2024,
2030
Table 14.3 Global Rheumatoid Arthritis Market by Region: CAGR (%), 2018, 2024, 2030

List of Figure
Figure 1.1 Global Rheumatoid Arthritis Drugs Market Segmentation Overview
Figure 3.1 Rheumatoid Arthritis Drugs Market: Market Share (%) by Indication, 2018
Figure 3.2 Rheumatoid Arthritis Drugs Market: Market Share (%) by Class, 2018
Figure 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
Figure 3.4 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class, 2018
Figure 3.5 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class, 2019
Figure 3.6 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class: CAGR (%), 2020-2030
Figure 3.7 The Rheumatoid Arthritis Drugs Market Segments: Revenue ($m) Forecast, 2018-2030
Figure 3.8 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018
Figure 3.9 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2024
Figure 3.10 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2030
Figure 3.11 Non-Biologics for Rheumatoid Arthritis: Revenue ($m) Forecasts by Segment, 2018-2030
Figure 3.12 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2018
Figure 3.13 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2024
Figure 3.14 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2030
Figure 3.15 Global NSAIDs Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
Figure 3.16 sDMARDs for Rheumatoid Arthritis Market Forecasts: Revenue ($ m), AGR (%), 2018-2030
Figure 3.17 Others Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
Figure 4.1 The Main Drugs in the Rheumatoid Arthritis Market: Market Shares (%), 2018
Figure 4.2 Global Humira Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.3 Global Enbrel Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.4 Global Remicade Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.5 Global Rituxan Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.6 Global Simponi/Simponi Aria Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.7 Global Orencia Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.8 Global Actemra/RoActemra Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.9 Global Cimzia Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.10 Global Celebrex Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.11 Global Xeljanz Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 4.12 Global Arcoxia Market Forecast: Revenue ($m) AGR (%), 2018-2030
Figure 5.1 World Rheumatoid Arthritis Drugs Market: Revenues ($ m) by Region, 2018
Figure 5.2 World Rheumatoid Arthritis Drugs Market: Revenues ($m) by Region, 2019
Figure 5.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
Figure 5.4 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2019
Figure 5.5 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2024
Figure 5.6 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2030
Figure 6.1 North America Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
Figure 6.2 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2019
Figure 6.3 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2024
Figure 6.4 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2030
Figure 6.5 U.S. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 6.6 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues($m), AGR (%), 2018-2030
Figure 7.1 Europe Rheumatoid Arthritis Drugs Market: Revenues ($m) by
Country/Sub-region, 2018
Figure 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
Figure 7.3 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
Figure 7.4 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
Figure 7.5 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
Figure 7.6 Germany Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 7.7 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 7.8 U.K. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 7.9 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 7.10 Spain Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 7.11 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 7.12 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 8.1 Asia Pacific Rheumatoid Arthritis Drugs Market: Revenues ($m) by
Country/Sub-region, 2018
Figure 8.2 Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030
Figure 8.3 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
Figure 8.4 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
Figure 8.5 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
Figure 8.6 Japan Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 8.7 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 8.8 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 8.9 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.1 Latin America Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018
Figure 9.2 Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
Figure 9.3 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
Figure 9.4 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
Figure 9.5 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
Figure 9.6 Brazil Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.7 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 9.6 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.1 Middle East & Africa (MEA) Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018
Figure 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030
Figure 10.3 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018
Figure 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024
Figure 10.5 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030
Figure 10.6 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.7 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 10.8 Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030
Figure 12.1 AbbVie: Revenue ($m), AGR (%), 2014-2018
Figure 12.2 AbbVie: Business Segment Revenue Share (%), 2018
Figure 12.3 AbbVie: Region Revenue Share (%), 2018
Figure 12.4 Roche: Revenue ($m), AGR (%), 2014-2018
Figure 12.5 Roche: Business Segment Revenue Share (%), 2018
Figure 12.6 Roche: Breakdown of Revenue (%) by Pharmaceuticals Drug, 2018
Figure 12.7 Johnson & Johnson: Revenue ($m), AGR (%), 2014-2018
Figure 12.8 Johnson & Johnson: by Business Segments Revenue Share (%), 2018
Figure 12.9 Johnson & Johnson: by Region Revenue Share (%), 2018
Figure 12.10 Amgen Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 12.11 Amgen Inc.: Business Segment Revenue Share (%), 2018
Figure 12.12 Amgen Inc.: Region Revenue Share (%), 2018
Figure 12.13 Pfizer, Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 12.14 Pfizer, Inc.: Business Segment Revenue Share (%), 2018
Figure 12.15 Pfizer, Inc: Region Revenue Share (%), 2018
Figure 12.16 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018
Figure 12.17 Merck & Co., Inc.: Business Segment Revenue Share (%), 2018
Figure 12.18 Merck & Co., Inc.: by Region Revenue Share (%), 2018
Figure 12.19 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2014-2018
Figure 12.20 Bristol-Myers Squibb: Business Segment Revenue Share (%), 2018
Figure 12.21 Bristol-Myers Squibb: by Region Revenue Share (%), 2018
Figure 12.22 UCB: Revenue ($m), AGR (%), 2014-2018
Figure 12.23 UCB: Business Segment Revenue Share (%), 2018
Figure 12.24 UCB: by Region Revenue Share (%), 2018
Figure 12.25 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018
Figure 12.26 Eli Lilly and Company: Business Segment Revenue Share (%), 2018
Figure 12.27 Eli Lilly and Company: by Region Revenue Share (%), 2018
Figure 12.28 Novartis AG: Revenue ($m), AGR (%), 2014-2018
Figure 12.29 Novartis AG: Business Segment Revenue Share (%), 2018
Figure 12.30 Novartis AG: by Region Revenue Share (%), 2018
Figure 12.31 Sanofi: Revenue ($m), AGR (%), 2014-2018
Figure 12.32 Sanofi: Business Segment Revenue Share (%), 2018
Figure 12.33 Sanofi: by Region Revenue Share (%), 2018
Figure 14.1 RA Drugs Market: Comparison of Revenue ($m Forecasts for Total Market and Market for RA Indication, 2018-2030
Figure 14.2 Global Rheumatoid Arthritis Market Forecast: Revenue ($m) 2018, 2024, 2030
Figure 14.3 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018
Figure 14.4 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2024
Figure 14.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2030
Figure 14.6 The Leading Drugs in the RA Market: Revenue ($m) Forecasts, 2018, 2024, 2030
Figure 14.7 The Global Rheumatoid Arthritis Market Forecast by Region: Revenue ($m), 2018, 2024, 2030